COVID-19 TREATMENTS 

We now offer infusion treatments and anti-viral

medications for eligible patients.

shutterstock_1769705054 (2).jpg
COVID-19 Treatments
Monoclonal Antibody Treatments

O

For those who have tested positive for COVID-19, Hayat is offering treatment options to help reduce progression to severe illness, especially for high-risk patients.Treatments should be started as soon as possible.

 

To determine if you qualify for these outpatient COVID-19 treatments, depending on your age, health history, and how long you have had symptoms, please call us at (414) 483-0000. 

Visit the page [what link] to  learn more.

 

Antiviral Medications
Traveling? We offer PCR COVID-19 test results and official immunization records with QR codes.

Our coronavirus PCR test is at no cost to you and testing is available seven days a week. Schedule your test at our drive-up site nearest you. Monoclonal antibody infusion treatments and antiviral medications may prevent severe illness, hospitalization and death in high-risk patients who have been infected with COVID-19. They help the immune system recognize and respond effectively to the virus. Right now, these treatment options, including Sotrovimab, Paxlovid, Molnupiravir and Remdesivir, have extremely limited supply. These treatment options require an evaluation by a licensed physician and an order or prescription, so please contact your primary care provider in Illinois or Wisconsin.

 

For those who have tested positive for COVID-19, Hayat is offering infusion treatments and anti-viral medication options to help reduce progression to severe illness, especially for high-risk patients.

 

To determine if you qualify - depending on your age, health history and how long you have had symptoms - or if it is covered by your health plan, please call us at (414) 483-0000.

Monoclonal Antibody (mAbs) Treatment

The REGEN-COV (CASIRIVIMAB AND IMDEVIMAB) monoclonal antibody treatment (mAb) can block the SARS-CoV-2 virus (the virus that causes COVID-19) from entering cells in your body and limit the amount of the virus within your body. This means you may have milder symptoms and it may decrease the likelihood of you needing to stay in the hospital.

The mAb treatment may help prevent certain people who are at high risk of exposure to someone who is infected with SARS-CoV-2 from getting the infection. It also may help people who: 

  • Are at high risk of getting more serious symptoms and

  • Have a positive COVID-19 test with symptoms for 10 days or less or

  • Have been in close contact with someone who has recently tested positive

The treatment is provided as soon as possible after results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset. It is administered via a subcutaneous injection by trained pharmacy staff.  

Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization of REGEN-COV (casirivimab and imdevimab)

Monoclonal Antibody Treatment Referral Form for Providers

Antiviral Medications

These COVID-19 medications are authorized for patients who have tested positive and can shorten the duration of the illness and lessen complications in some people.

Paxlovid - oral antiviral tablets

For faster treatment of COVID-19 we can now prescribe Paxlovid within 5 days for those who test positive and are eligible. To determine if you qualify, bring a list of all medications you are taking and health records from the past year with recent reports of laboratory blood work to our drive-up COVID Service Center at 807 W. Layton Ave. in Milwaukee. Or call us in advance at (414) 483-0000 and we will consult with your healthcare provider.

Fact Sheet for Patients and Caregivers Emergency Use Authorization (EAU) of Paxlovid 

  • Recommended for patients who:

    • Are a high risk for progression to severe COVID-19 hospitalization 

    • Have symptoms consistent with mild-moderate COVID-19

    • Had symptom onset within 5 days

    • Have a prescription from their Primary Care Provider 

Molnupiravir - oral antiviral tablets

Fact Sheet for Patients and Caregivers Emergency Use Authorization (EUA) of Molnupiravir

  •  Recommended for patients who:

    • Are a high risk for progression to severe COVID-19 hospitalization

    • Have symptoms consistent with mild-moderate COVID-19

    • Had symptom onset within 5 days

    • Have a prescription from their Primary Care Provider

    • Are not pregnant

COVID-19 Treatments